FibroBiologics to Present Corporate Update at 2023 BIO International Convention
Clinical-Stage Company Focused on Advancing Fibroblast Cell-Based Therapies for Treatment of Chronic Diseases HOUSTON, June 1, 2023/PRNewswire/ – FibroBiologics, a clinical-stage company focused on the development of fibroblast cell-based therapeutics for chronic diseases, today announced that Pete O’Heeron, Founder and Chief Executive Officer, will present a corporate overview next week at the 2023 BIO International […]
FibroBiologics has released its annual report Form C-AR
FibroBiologics has released its annual report Form C-AR for the year ended December 31, 2022 – FibroBiologics is a clinical-stage cell therapy company focused on developing and commercializing fibroblast cell-based and fibroblast cell-derived product candidates as therapeutics for patients suffering from chronic diseases with significant unmet medical needs.
Podcast: Pete O’Heeron – Regenerative medicine and treating chronic disease with FibroBiologics
Kicking off the first episode of Founders Keepers of 2023 is Pete O’Heeron – the Founder and CEO of FibroBiologics. FibroBiologics is a clinical-stage regenerative medicine company based in Houston, Texas, developing a pipeline of treatments for chronic diseases using fibroblast cells. They hold over 150 US and international issued patents and patents pending across […]
